Research outputs

@article{Tan2026,

title = {Win Ratios in Ophthalmology-a Hierarchical Metric to Evaluate Adverse Outcomes in Comparative Studies},

author = {Jeremy C K Tan and George Kong and David Wechsler and David Manning and Hamish Dunn and Brian Chua and Helen Danesh-Meyer and Louis Arnould and Gus Gazzard and Mitchell Lawlor},

doi = {10.1016/j.xops.2026.101382},

issn = {2666-9145},

year  = {2026},

date = {2026-00-00},

urldate = {2026-00-00},

journal = {Ophthalmology Science},

volume = {6},

number = {11},

pages = {101382},

keywords = {Fight Glaucoma Blindness, Ophthalmology Science},

pubstate = {published},

tppubtype = {article}

}

@article{Chami2025,

title = {Comparative Study of Early Safety and Effectiveness Outcomes of the PreserFlo MicroShunt with and without an Intraluminal Suture Stent},

author = {Jason Chami and Jeremy C K Tan and David Manning and George Kong and Jason Cheng and Hamish Dunn and Anna Galanopoulos and Brian Chua and Joanne Thai and Mark Hassall and Jamie E Craig and Mitchell Lawlor},

doi = {10.1016/j.ogla.2025.03.003},

issn = {2589-4196},

year  = {2025},

date = {2025-00-00},

urldate = {2025-00-00},

journal = {Ophthalmology Glaucoma},

volume = {8},

number = {4},

pages = {367–374},

keywords = {Fight Glaucoma Blindness, Ophthalmology Glaucoma},

pubstate = {published},

tppubtype = {article}

}

@article{Tan2025,

title = {Association Between Prior Selective Laser Trabeculoplasty and Phaco-iStent Inject Efficacy},

author = {Jeremy C K Tan and Colin I Clement and Andrew White and Hamish Dunn and Bernardo Soares and David Wechsler and Vincent Lee and Mitchell Lawlor},

doi = {10.1111/ceo.14588},

issn = {1442-9071},

year  = {2025},

date = {2025-00-00},

urldate = {2025-00-00},

journal = {Clinical and Experimental Ophthalmology},

volume = {53},

number = {9},

pages = {1148–1155},

keywords = {Clinical and Experimental Ophthalmology, Fight Glaucoma Blindness},

pubstate = {published},

tppubtype = {article}

}

@article{Tan2025b,

title = {Long-term comparative outcomes of Hydrus versus iStent inject microinvasive glaucoma surgery implants combined with cataract surgery},

author = {Jeremy C K Tan and Colin Clement and Paul Healey and Ridia Lim and Andrew White and Joshua Yuen and Ashish Agar and Mitchell Lawlor},

doi = {10.1136/bjo-2025-327359},

issn = {1468-2079},

year  = {2025},

date = {2025-00-00},

urldate = {2025-00-00},

journal = {British Journal of Ophthalmology},

volume = {110},

number = {1},

pages = {52–58},

keywords = {British Journal of Ophthalmology, Fight Glaucoma Blindness},

pubstate = {published},

tppubtype = {article}

}

@article{Tan2025c,

title = {Impact of Different Intraocular Pressure and Medication Endpoint Criteria on Success Rates in Subconjunctival Minimally Invasive Glaucoma Surgery},

author = {Jeremy C K Tan and George Kong and Louis Arnould and Vincent Lee and Colin Clement and Jason Cheng and Gus Gazzard and Mitchell Lawlor},

doi = {10.1097/IJG.0000000000002639},

issn = {1536-481X},

year  = {2025},

date = {2025-00-00},

urldate = {2025-00-00},

journal = {Journal of Glaucoma},

volume = {34},

number = {11},

pages = {985–993},

keywords = {Fight Glaucoma Blindness, Journal of Glaucoma},

pubstate = {published},

tppubtype = {article}

}

@article{Tan2025d,

title = {Visual rehabilitation in subconjunctival MIGS versus trabeculectomy and tube shunt surgery},

author = {Jeremy C K Tan and Yohei Hashimoto and Hamish Dunn and David Wechsler and Shweta Kaushik and Louis Arnould and Andrew White and Mitchell Lawlor},

doi = {10.1016/j.ajoint.2025.100108},

issn = {2950-2535},

year  = {2025},

date = {2025-00-00},

urldate = {2025-00-00},

journal = {AJO International},

volume = {2},

number = {1},

pages = {100108},

keywords = {AJO International, Fight Glaucoma Blindness},

pubstate = {published},

tppubtype = {article}

}

@article{Clement2025,

title = {Longitudinal outcomes of iStent inject with cataract surgery compared with cataract surgery alone: real-world data from the Fight Glaucoma Blindness registry},

author = {Colin I. Clement and Vuong Nguyen and Frank Howes and Jenny Danks and Vincent Lee and David Wechsler and Emily Gregory-Roberts and Mark Gillies and Mitchell Lawlor},

doi = {10.1097/j.jcrs.0000000000001567},

issn = {1873-4502},

year  = {2025},

date = {2025-00-00},

urldate = {2025-00-00},

journal = {Journal of Cataract and Refractive Surgery},

volume = {51},

number = {2},

pages = {113–118},

publisher = {Ovid Technologies (Wolters Kluwer Health)},

abstract = {Purpose: To compare combined phacoemulsification and iStent inject with phacoemulsification alone. Setting: Fight Glaucoma Blindness (FGB) registry, Sydney, Australia. Design: Prospective observational registry study. Methods: Eyes that had combined phacoemulsification with iStent inject (iStent group)},

keywords = {Fight Glaucoma Blindness, Journal of Cataract and Refractive Surgery},

pubstate = {published},

tppubtype = {article}

}

@article{Arnould2024,

title = {Two-year outcomes of Xen 45 gel stent implantation in patients with open-angle glaucoma: real-world data from the Fight Glaucoma Blindness registry},

author = {Louis Arnould and Elise Balsat and Yohei Hashimoto and Andrew White and George Kong and Hamish Dunn and Leo Fan and Pierre-Henry Gabrielle and Alain M Bron and Catherine P Creuzot-Garcher and Mitchell Lawlor},

doi = {10.1136/bjo-2023-325077},

issn = {1468-2079},

year  = {2024},

date = {2024-12-00},

journal = {British Journal of Ophthalmology},

volume = {108},

number = {12},

pages = {1672–1678},

publisher = {BMJ},

abstract = {Objective To evaluate efficacy and safety outcomes of the Xen 45 gel stent implant over 24 months of follow-up. Methods A retrospective analysis of prospectively collected data from the Fight Glaucoma Blindness observational registry. Complete success (CS) was defined as intraocular pressure (IOP) reduction ≥20% from preoperative and an IOP ≤18 mm Hg and ≥6 mm Hg with no secondary procedure at 2 years and without IOP-lowering medications. Qualified success (QS) was defined similarly, allowing the use of IOP-lowering medications. Results The Xen 45 gel stent implant was implanted in 646 eyes of 515 patients. Preoperative IOP was 21.4±7.6 (mean±SD) mm Hg on 2.7±1.3 IOP-lowering medication and mean deviation was −10.2±8.4 dB. After 24-month follow-up, IOP was 16.8±7.3 mm Hg (mean reduction of 21.7%) on 1.2±1.4 IOP-lowering medications. CS and QS rates at 24 months were 26% and 48%, respectively. CS and QS were higher in the Xen stand-alone group (33% and 52%, respectively) than in the Xen+cataract group (16% and 42%, respectively). Bleb needling was performed in 28.4% of cases, and 18% underwent a secondary procedure. Conclusions The Xen 45 gel stent implant offers acceptable long-term efficacy for the treatment of open-angle glaucoma. However, there is a significant rate of reoperation and needling, and outcomes are less effective if combined with cataract surgery.},

keywords = {British Journal of Ophthalmology, Fight Glaucoma Blindness},

pubstate = {published},

tppubtype = {article}

}

@article{Huynh2024,

title = {Outcomes of iStent inject combined with cataract surgery in Asian eyes: Australian data from the Fight Glaucoma Blindness international registry},

author = {Brandon Huynh and Getiye Kibret and David Wechsler and Anne Lee and Ridia Lim and Colin Clement and Mitchell Lawlor},

doi = {10.1007/s10792-024-03104-x},

issn = {1573-2630},

year  = {2024},

date = {2024-12-00},

journal = {International Ophthalmology},

volume = {44},

number = {1},

publisher = {Springer Science and Business Media LLC},

keywords = {Fight Glaucoma Blindness, International Ophthalmology},

pubstate = {published},

tppubtype = {article}

}

@article{Tan2024,

title = {Outcomes and Baseline Predictors of Failure in Primary Standalone Xen45 Gel Stent versus Trabeculectomy for Glaucoma},

author = {Jeremy C. K. Tan and Yohei Hashimoto and Pierre Henry Gabrielle and Catherine Creuzot Garcher and Andrew White and Hamish Dunn and Mark Walland and David Wechsler and Louis Arnould and Mitchell Lawlor},

doi = {10.1016/j.ogla.2024.07.002},

issn = {2589-4196},

year  = {2024},

date = {2024-11-00},

journal = {Ophthalmology Glaucoma},

volume = {7},

number = {6},

pages = {539–550},

publisher = {Elsevier BV},

keywords = {Fight Glaucoma Blindness, Ophthalmology Glaucoma},

pubstate = {published},

tppubtype = {article}

}

@article{Clement2024,

title = {12-month Safety and Efficacy Outcomes of a Standalone Trabecular Bypass Device},

author = {Colin Clement and Jed Lusthaus and Ridia Lim and David Manning and Brandon Huynh and Vuong Nguyen and Stephen O'Hagan and Frank Howes and Peter Macken and Mitchell Lawlor},

doi = {10.5005/jp-journals-10078-1447},

issn = {0975-1947},

year  = {2024},

date = {2024-00-00},

journal = {Journal of Current Glaucoma Practice},

volume = {18},

number = {3},

pages = {103–109},

publisher = {Jaypee Brothers Medical Publishing},

keywords = {Fight Glaucoma Blindness, Journal of Current Glaucoma Practice},

pubstate = {published},

tppubtype = {article}

}

@article{Holmes2022,

title = {Comparative study of 2‐year outcomes for Hydrus or iStent inject microinvasive glaucoma surgery implants with cataract surgery},

author = {David P. Holmes and Colin I. Clement and Vuong Nguyen and Paul R. Healey and Ridia Lim and Andrew White and Joshua Yuen and Mitchell Lawlor},

doi = {10.1111/ceo.14048},

issn = {1442-9071},

year  = {2022},

date = {2022-04-00},

journal = {Clinical and Experimental Ophthalmology},

volume = {50},

number = {3},

pages = {303–311},

publisher = {Wiley},

abstract = {Background To compare real‐world 24‐month outcomes of phacoemulsification combined with either iStent inject or Hydrus Microstent. Methods Analysis of data from the Fight Glaucoma Blindness (FGB) international registry. Anonymized data from 344 eyes with mild‐to‐moderate open‐angle glaucoma, normal‐tension glaucoma or ocular hypertension that underwent phacoemulsification combined with either iStent inject (224) or Hydrus Microstent (120) were included. Data were adjusted for baseline characteristics using linear regression and propensity score matching. The primary endpoint was a comparison of mean intraocular pressure (IOP) at 24 months. Results At 24 months, there was no significant difference in IOP reduction between the two groups, consistent across all analyses. The matched cohort showed iStent inject achieved 3.1 mmHg reduction and Hydrus a 2.3 mmHg reduction ( p = 0.530) and a mean medication reduction of 1.0 for iStent inject versus 0.5 for Hydrus ( p = 0.081). 5.4% of eyes in the iStent inject group and 7.5% of eyes in the Hydrus group required subsequent procedures to improve IOP control within 24 months. Complications were rare with no significant differences between the groups. Conclusions Twenty‐four‐month outcomes showed sustained IOP reduction with a good safety profile for both groups. There was no significant difference in IOP outcomes between the groups. There may be a small additional reduction in glaucoma medication usage following cataract surgery with iStent inject compared to Hydrus.},

keywords = {Clinical and Experimental Ophthalmology, Fight Glaucoma Blindness},

pubstate = {published},

tppubtype = {article}

}

@article{Lawlor2021,

title = {Efficient capture of high-quality real-world data on treatments for glaucoma: the Fight Glaucoma Blindness! Registry},

author = {Mitchell Lawlor and Vuong Nguyen and Anne Brooks and Colin Clement and Jamie E Craig and Helen Danesh-Meyer and Ivan Goldberg and Stuart L Graham and John R Grigg and Frank Howes and Ridia Lim and Simon E Skalicky and Andrew J White and Mark Gillies},

doi = {10.1136/bmjophth-2021-000903},

issn = {2397-3269},

year  = {2021},

date = {2021-11-00},

journal = {BMJ Open Ophthalmology},

volume = {6},

number = {1},

publisher = {BMJ},

abstract = {Objective To describe the development and implementation of a web-based high-quality data collection tool to track the outcomes of glaucoma treatments in routine practice. Methods and analysis This is a prospective observational registry study. An international steering committee undertook an iterative structured process to define a minimum, patient-centred data set designed to track outcomes of glaucoma treatment. The outcomes were coded into a web-based programme allowing easy access for rapid data entry. Clinicians receive personal reports enabling instant audit of their outcomes. Analyses of aggregated anonymised data on real-world outcomes are analysed and periodically reported with the goal of improving patient care. Results The minimum data set developed by the international steering committee includes the following: a baseline visit captures 13 mandatory fields in order to accurately phenotype each patient’s subtype of glaucoma and to allow comparison between services, and a follow-up visit includes only four mandatory fields to allow completion within 30 s. Currently, there are 157 surgeons in 158 ophthalmology practices across Australia and New Zealand who are registered. These surgeons are tracking 5570 eyes of 3001 patients and have recorded 67 074 visits. The median number of eyes per surgeon is 22 eyes with a range of 1–575. The most common glaucoma procedure, excluding cataract surgery, is iStent inject, with 2316 cases. Conclusion This software tool effectively facilitates data collection on safety and efficacy outcomes of treatments for different subgroups of glaucoma within a real-world setting. It provides a template to evaluate new treatments as they are introduced into practice.},

keywords = {BMJ Open Ophthalmology, Fight Glaucoma Blindness},

pubstate = {published},

tppubtype = {article}

}